Neutralization Activity and Persistence of Antibodies Induced in Response to Vaccination with a Novel Mumps Strain, RIT 4385

Usonis, Vytautas; Bakasenas, V.; Denis, Martine

doi:10.1007/s15010-001-1098-7

Cited by 17 publications

(9 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For mumps and rubella antibodies, our results seem to be better than those with MMR II. Similarly, the degree of persistence of mumps antibodies in our study was higher than those reported by Usonis et al (9).…”

contrasting

confidence: 61%

Persistence of Antibodies Induced by Measles-Mumps-Rubella Vaccine in Children in India

Raut

Kulkarni

Phadke

et al. 2007

Clin Vaccine Immunol

View full text Add to dashboard Cite

Antibody levels in 41 Indian girls were measured 6 years after measles-mumps-rubella (MMR) vaccination. Rates of seropositivity were 88% (measles antibodies), 95% (mumps antibodies), and 100% (rubella antibodies). The MMR vaccine induces long-term immunity in a majority of vaccinees; however, due to the observation of some seronegative vaccinees, the policy of administering a second dose of the MMR vaccine seems appropriate.Measles outbreaks in immunized populations have been reported previously (7,13). Similarly, mumps outbreaks in highly vaccinated populations (4, 10), including the recent large epidemic in the United States (5), have occurred. Both primary vaccine failure and waning immunity are responsible for the outbreaks in vaccinated populations. The infective dose and the vaccine strain are important factors for long-lasting immunity (6).In India, the measles-mumps-rubella (MMR) vaccine is manufactured by the Serum Institute of India Ltd. at Pune. The vaccine contains Edmonston-Zagreb measles virus, Leningrad-Zagreb mumps virus, and RA 27/2 rubella virus. Studies of Indian children using this vaccine have shown over 95% seroconversion against measles and rubella and 90% seroconversion against mumps (2, 12). The antibody persistence study would indicate the likely duration of protection afforded by the vaccine. Therefore, the present study was undertaken to assess the antibody titers persisting in a previously vaccinated pediatric population.In November and December 1999, 99 healthy children aged 1 to 10 years from Kusumbai Motichand Mahila Seva Gram, Karve Road, Pune, an organization for the rescue and rehabilitation of women and children, were given a single dose of an MMR vaccine (Serum Institute of India Ltd.) for the first time. The present study was conducted between April and August 2005 to assess the persistence of antibodies. The serological tests were conducted in the quality control department of the Serum Institute of India Ltd.The study was approved by the ethics committee of the Serum Institute of India Research Foundation. Informed written consent from the legal guardian of each child or the warden of the institute and signed assent from the subjects were obtained. Forty-one children from this group were available for follow-up in 2005. Acute febrile illness, any other infection, conditions associated with immunosuppression, the receipt of immunosupressive therapy, and participation in any other clinical trial within 1 month before and during the course of the study were criteria for exclusion.In 1999, the batch number of the vaccine used was 320-V (expiration date, August 2001). A 0.5-ml dose of reconstituted vaccine was given subcutaneously. In 2005, measles and rubella immunoglobulin G (IgG) antibodies were assayed by the enzyme-linked immunosorbent assay technique using Trinity Biotech kits. Mumps IgG antibodies were assayed by using a Calbiotech Inc. kit. For measles and rubella antibodies, immune status ratios of Ն1.1 were interpreted as seropositive. For data analysis, values below ...

show abstract

contrasting

confidence: 61%

Persistence of Antibodies Induced by Measles-Mumps-Rubella Vaccine in Children in India

Raut

Kulkarni

Phadke

et al. 2007

Clin Vaccine Immunol

View full text Add to dashboard Cite

show abstract

“…The decline of immunity to these viruses after administration of a first dose of MMRV vaccine was comparable to that in the control group of children who had received a first dose of a standard MMR vaccine during the second year of life and in keeping with the results of previous studies of antibody persistence after a first dose of MMR. 17,18 The 85% of subjects in the MMRV group seropositive for varicella antibodies 4 to 5 years after administration of the first vaccine dose (all had been seropositive 6 weeks after the first dose) are in keeping with the results of other studies of antibody persistence following varicella vaccination 8,10,19 as well as estimates of vaccine efficacy after a single dose (87% overall ͓95% CI: 81-91%͔; 97% in the first year after vaccination declining to 84% 2-8 years after vaccination) 6 supporting the need for administration of a second dose of varicella vaccine for optimum protection. 9 In this study, administration of a second dose of MMRV vaccine was immunogenic in children who had previously received a first dose of this vaccine and in those who had received a first dose of a standard MMR vaccine during the second year of life.…”

Section: Discussionmentioning

confidence: 99%

Immunogenicity and Safety of a Second Dose of Measles???Mumps???Rubella???Varicella Vaccine in Healthy Children Aged 5 to 6 Years

Vesikari¹,

Baer²,

Willems³

2007

The Pediatric Infectious Disease Journal

View full text Add to dashboard Cite

show abstract

“…10 Although the serologic correlate of protection induced by mumps vaccination has not been accepted yet, the neutralizing antibodies have been considered as the most probable candidate. [22][23][24][25][26] Regarding animal models, although guinea pigs, mice, cotton rats, rabbits and hamsters are not susceptible to MuV infection, they do generate neutralizing antibodies upon mumps administration. 27 In such a situation, we chose to establish and optimize immunogenicity assay in guinea pigs measuring quantity of functional virus-specific antibodies raised upon immunization of animals with MuV.…”

Section: Introductionmentioning

confidence: 99%

Factors influencing preclinicalin vivoevaluation of mumps vaccine strain immunogenicity

Halassy

Kurtović

Brgles

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Keywords: design of Experiments (DoE), in vivo bioassay optimization, mumps virus, non-clinical vaccine immunogenicity assessmentImmunogenicity testing in animals is a necessary preclinical assay for demonstration of vaccine efficacy the results of which are often the basis for the decision whether to proceed or withdraw the further development of the novel vaccine candidate. However, in vivo assays are rarely, if at all, optimized and validated. Here we clearly demonstrate the importance of in vivo assay (mumps virus immunogenicity testing in guinea pigs) optimization for gaining reliable results and the suitability of Fractional factorial design of experiments (DoE) for such a purpose. By the use of DoE with resolution IV (2 IV (4-1) ) we clearly revealed that the parameters significantly increasing assay sensitivity were interval between animal immunizations followed by the body weight of experimental animals. The quantity (0 versus 2%) of the stabilizer (fetal bovine serum, FBS) in the sample was shown as non-influencing parameter in DoE setup. However, the separate experiment investigating only the FBS influence, and performed under other parameters optimally set, showed that FBS also influences the results of immunogenicity assay. Such finding indicated that (a) factors with strong influence on the measured outcome can hide the effects of parameters with modest/low influence and (b) the matrix of mumps virus samples to be compared for immunogenicity must be identical for reliable virus immunogenicity comparison. Finally the 3 mumps vaccine strains widely used for decades in the licensed vaccines were for the first time compared in an animal model, and results obtained were in line with their reported immunogenicity in human population supporting the predictive power of the optimized in vivo assay.

show abstract

Neutralization Activity and Persistence of Antibodies Induced in Response to Vaccination with a Novel Mumps Strain, RIT 4385

Abstract: These data suggest that both vaccines provided equivalent protection against mumps over this 18-month period.

Cited by 17 publications

References 12 publications

Persistence of Antibodies Induced by Measles-Mumps-Rubella Vaccine in Children in India

Persistence of Antibodies Induced by Measles-Mumps-Rubella Vaccine in Children in India

Immunogenicity and Safety of a Second Dose of Measles???Mumps???Rubella???Varicella Vaccine in Healthy Children Aged 5 to 6 Years

Factors influencing preclinicalin vivoevaluation of mumps vaccine strain immunogenicity

Contact Info

Product

Resources

About